EffRx Pharmaceuticals has an experienced management team with savvy knowledge of biopharmaceuticals across international regions and in various therapeutic areas.
EffRx leverages this collective expertise in medical affairs, clinical development, regulatory affairs, market access, commercialization and operations to build an international pharmaceutical business through successful partnerships and necessitated therapeutics.
Copyright © 2024 All rights reserved
Web Design by Solvia
Mr. Bosisio, CEO of EffRx Pharmaceuticals since 2016, has solid experience across different therapeutic areas in bringing medicines from the development stage to the market. He served as Chief Commercial Officer for Tissot Medical Research and as EMEA Marketing Director for Alexion. During his 9 years tenure with Amgen, he built from scratch the international commercial infrastructure for the flagship drug denosumab, launched Prolia®, optimized Aranesp® and launched Mimpara®. At PwC Switzerland he led Marketing and Business Development for its major practice. Earlier in his career, he set up the commercial organization and led Marketing & Sales for a start-up.
Mr. Bosisio holds a BSc in Economics & Business Administration and has earned an MBA from HEC School of Management, Paris.
Mr. Paolo Agnoluzzi became the Chief Financial Officer in 2017. Since joining, he successfully executed several debt and equity transactions, including several capital increases (authorized and conditional) and an M&A transaction.
Most recently, Mr. Agnoluzzi served as Finance Director for VistaJet Group Holding SA. His responsibilities included acting as deputy CFO, leading the financial planning and analysis group, heading the treasury function and directing special projects within Finance.
Prior to VistaJet, Mr. Agnoluzzi held the position of Director Finance Europe and Commercial Head DACH Region at Endocyte Europe GmbH. Previously to Endocyte, he spent 20 years at Amgen serving various senior financial positions, including among others, Head of Finance Oncology, Bone and New Products and Director Finance & Administration.
Dr. Lichtlen, Chief Medical Advisor at EffRx, previously served as Chief Medical Officer (CMO) at Sucampo Pharmaceuticals, Inc (Nasdaq: SCMP) until its $1.2B acquisition by Mallinckrodt in early 2018.
He is also a founder and the CMO at Numab Therapeutics AG in Switzerland. Prior to co-founding Numab Therapeutics AG in 2011, Dr. Lichtlen was the Head of Clinical R&D at ESBATech AG (acquired by Alcon/Novartis in 2009) until the end of 2010. Besides his CMO role at Numab Therapeutics AG and his consultancy role at EffRx, Dr. Lichtlen also serves as scientific advisor to GF Group Holding AG, Switzerland.
Dr. Ghielmetti brings 14+ years of relevant experience in the pharmaceutical industry. Her areas of competence include product launch excellence, life cycle management, strategic medical affairs planning, medical operational excellence, medical information, and pharmacovigilance (QPPV). She worked across different therapeutic areas such as neuroscience, allergology/immunology and respiratory diseases at Novartis and Biogen.
Dr. Ghielmetti is a pharmacist by training with a PhD in Immunology from the University of Bern (CH). She further holds a Diploma of Advanced Studies in Pharmaceutical Medicine from the University of Basel (CH).
Ms. Christiane Sievert is the Head of Regulatory Affairs at EffRx. She previously worked at Stragen Pharma as VP & Head of Regulatory Affairs. Her Regulatory Affairs experience spans the pharmaceutical value chain, from early development to life-cycle management. Further, she brings proven, in-depth knowledge in RA across international markets, firsthand experience in interacting with Health Authorities, as well as expertise in setting up, leading & optimizing RA processes and infrastructures.
Ms. Sievert holds a Dipl. Ing. in Pharmaceutical Chemistry and has a broad therapeutic area experience in both blue-chip as well as smaller entrepreneurial biopharmaceutical companies.
Mr. Victor Papavasileiou has over 15 years of experience in the pharma and biotech industry in business, corporate development and strategy. He has a track record of developing profitable product portfolios in therapeutic areas of strategic interest through M&A and licensing and specializes in SME turnaround and growth.
Prior to joining EffRx, he led business development at Lacer, a major Spanish pharmaceutical company, and more recently in Navamedic, a listed pharmaceutical and Medtech company covering the Nordic markets.
Victor holds an M.Sc. in Biotechnology and Biochemical Engineering from UCL in London, a Professional Doctorate in Engineering from the TU Delft in the Netherlands and an MBA from Kellogg.
Dr. Nathalie Véron, Director Technical Operations at EffRx, is responsible for the operational activities such as product supply, quality assurance and IP management.
Prior to joining EffRx, she has held various local and global, cross-functional leadership positions in Manufacturing Science and Technology at F. Hoffmann-La Roche, Technical Operations. In addition, she significantly contributed to Digital Supply Chain and Quality Transformation projects in the pharmaceutical industry.
Dr. Véron is a pharmacist by education, who graduated from the University of Freiburg, Germany. She holds a PhD in Biology from the Free University Berlin, Germany and has over 10 years of experience as a Biomedical Scientist.
Michael Schmid is the International Marketing Director of EffRx.
Prior to joining EffRx, Mr. Schmid served as Global Brand Lead at Takeda Pharmaceuticals, where he was responsible for the world’s top-selling medicinal calcium and vitamin D supplement. Other previous positions include Brand Leader Specialist Accounts, Commercial Operations Emerging Markets (Takeda), and Senior Global Brand Manager at Nycomed. Michael studied pharmacy at the ETH in Zurich.
Mr. Schmid has over 25 years of experience in the pharmaceutical industry, working across a wide range of therapeutic areas, including osteoporosis, gastroenterology and pain management.
Mr. Roger Iseli is the National Head of Sales in Switzerland.
Roger is a seasoned professional with a strong foundation in sales management in the pharmaceutical industry. He brings over 30 years of professional experience and has cultivated his expertise across multiple therapeutic areas. In his career he has steered national sales teams for esteemed organizations including Novartis, Essex Pharma, Eli Lilly, Amgen, Bayer, and Novo Nordisk, has spearheaded the successful launch of several blockbuster drugs and has developed profitable product portfolios.
Roger Iseli studied chemistry at the Technical University of Winterhur.
